Literature DB >> 24980705

New insights concerning the molecular basis for defective glucoregulation in soluble adenylyl cyclase knockout mice.

George G Holz1, Colin A Leech2, Oleg G Chepurny2.   

Abstract

Recently published findings indicate that a knockout (KO) of soluble adenylyl cyclase (sAC, also known as AC-10) gene expression in mice leads to defective glucoregulation that is characterized by reduced pancreatic insulin secretion and reduced intraperitoneal glucose tolerance. Summarized here are current concepts regarding the molecular basis for this phenotype, with special emphasis on the potential role of sAC as a determinant of glucose-stimulated insulin secretion. Highlighted is new evidence that in pancreatic beta cells, oxidative glucose metabolism stimulates mitochondrial CO₂production that in turn generates bicarbonate ion (HCO(3)(-)). Since HCO(3)(-) binds to and directly stimulates the activity of sAC, we propose that glucose-stimulated cAMP production in beta cells is mediated not simply by transmembrane adenylyl cyclases (TMACs), but also by sAC. Based on evidence that sAC is expressed in mitochondria, there exists the possibility that beta-cell glucose metabolism is linked to mitochondrial cAMP production with consequent facilitation of oxidative phosphorylation. Since sAC is also expressed in the cytoplasm, sAC catalyzed cAMP production may activate cAMP sensors such as PKA and Epac2 to control ion channel function, intracellular Ca²⁺ handling, and Ca²⁺-dependent exocytosis. Thus, we propose that the existence of sAC in beta cells provides a new and unexpected explanation for previously reported actions of glucose metabolism to stimulate cAMP production. It seems possible that alterations of sAC activity might be of importance when evaluating new strategies for the treatment of type 2 diabetes (T2DM), or when evaluating why glucose metabolism fails to stimulate insulin secretion in patients diagnosed with T2DM. This article is part of a Special Issue entitled: The role of soluble adenylyl cyclase in health and disease.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bicarbonate ion; Glucose; Insulin secretion; Soluble adenylyl cyclase; cAMP

Mesh:

Substances:

Year:  2014        PMID: 24980705      PMCID: PMC4262651          DOI: 10.1016/j.bbadis.2014.06.023

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  138 in total

1.  Induction of glucose competence in pancreatic beta cells by glucagon-like peptide-1(7-37).

Authors:  G H Holz; W M Kuhtreiber; J F Habener
Journal:  Trans Assoc Am Physicians       Date:  1992

2.  Facilitation of ß-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac.

Authors:  Colin A Leech; Igor Dzhura; Oleg G Chepurny; Frank Schwede; Hans-G Genieser; George G Holz
Journal:  Islets       Date:  2010 Mar-Apr       Impact factor: 2.694

Review 3.  Glucose-sensing mechanisms in pancreatic beta-cells.

Authors:  Patrick E MacDonald; Jamie W Joseph; Patrik Rorsman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

4.  Crystal structures of human soluble adenylyl cyclase reveal mechanisms of catalysis and of its activation through bicarbonate.

Authors:  Silke Kleinboelting; Ana Diaz; Sebastien Moniot; Joop van den Heuvel; Michael Weyand; Lonny R Levin; Jochen Buck; Clemens Steegborn
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-24       Impact factor: 11.205

5.  Rapid glucose sensing by protein kinase A for insulin exocytosis in mouse pancreatic islets.

Authors:  Hiroyasu Hatakeyama; Takuya Kishimoto; Tomomi Nemoto; Haruo Kasai; Noriko Takahashi
Journal:  J Physiol       Date:  2005-11-10       Impact factor: 5.182

Review 6.  Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

Authors:  Steven E Kahn; Mark E Cooper; Stefano Del Prato
Journal:  Lancet       Date:  2013-12-03       Impact factor: 79.321

7.  Human islet glucokinase gene. Isolation and sequence analysis of full-length cDNA.

Authors:  L I Koranyi; Y Tanizawa; C M Welling; D U Rabin; M A Permutt
Journal:  Diabetes       Date:  1992-07       Impact factor: 9.461

Review 8.  cAMP and mitochondria.

Authors:  Federica Valsecchi; Lavoisier S Ramos-Espiritu; Jochen Buck; Lonny R Levin; Giovanni Manfredi
Journal:  Physiology (Bethesda)       Date:  2013-05

9.  Pancreatic β-cell response to increased metabolic demand and to pharmacologic secretagogues requires EPAC2A.

Authors:  Woo-Jin Song; Prosenjit Mondal; Yuanyuan Li; Suh Eun Lee; Mehboob A Hussain
Journal:  Diabetes       Date:  2013-04-11       Impact factor: 9.461

10.  Age-dependent labeling and imaging of insulin secretory granules.

Authors:  Anna Ivanova; Yannis Kalaidzidis; Ronald Dirkx; Mihail Sarov; Michael Gerlach; Britta Schroth-Diez; Andreas Müller; Yanmei Liu; Cordula Andree; Bernard Mulligan; Carla Münster; Thomas Kurth; Marc Bickle; Stephan Speier; Konstantinos Anastassiadis; Michele Solimena
Journal:  Diabetes       Date:  2013-08-08       Impact factor: 9.461

View more
  10 in total

1.  Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α.

Authors:  M Ahsan Siraj; Dhanwantee Mundil; Sanja Beca; Abdul Momen; Eric A Shikatani; Talat Afroze; Xuetao Sun; Ying Liu; Siavash Ghaffari; Warren Lee; Michael B Wheeler; Gordon Keller; Peter Backx; Mansoor Husain
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

2.  Rp-cAMPS Prodrugs Reveal the cAMP Dependence of First-Phase Glucose-Stimulated Insulin Secretion.

Authors:  Frank Schwede; Oleg G Chepurny; Melanie Kaufholz; Daniela Bertinetti; Colin A Leech; Over Cabrera; Yingmin Zhu; Fang Mei; Xiaodong Cheng; Jocelyn E Manning Fox; Patrick E MacDonald; Hans-G Genieser; Friedrich W Herberg; George G Holz
Journal:  Mol Endocrinol       Date:  2015-06-10

3.  Restoration of Glucose-Stimulated Cdc42-Pak1 Activation and Insulin Secretion by a Selective Epac Activator in Type 2 Diabetic Human Islets.

Authors:  Rajakrishnan Veluthakal; Oleg G Chepurny; Colin A Leech; Frank Schwede; George G Holz; Debbie C Thurmond
Journal:  Diabetes       Date:  2018-07-09       Impact factor: 9.461

4.  Bithionol Potently Inhibits Human Soluble Adenylyl Cyclase through Binding to the Allosteric Activator Site.

Authors:  Silke Kleinboelting; Lavoisier Ramos-Espiritu; Hannes Buck; Laureen Colis; Joop van den Heuvel; J Fraser Glickman; Lonny R Levin; Jochen Buck; Clemens Steegborn
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

5.  Cross-Talk Between the Adenylyl Cyclase/cAMP Pathway and Ca2+ Homeostasis.

Authors:  Jose Sanchez-Collado; Jose J Lopez; Isaac Jardin; Gines M Salido; Juan A Rosado
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

6.  Pancreatic Beta Cell G-Protein Coupled Receptors and Second Messenger Interactions: A Systems Biology Computational Analysis.

Authors:  Leonid E Fridlyand; Louis H Philipson
Journal:  PLoS One       Date:  2016-05-03       Impact factor: 3.240

Review 7.  Beta cell connectivity in pancreatic islets: a type 2 diabetes target?

Authors:  Guy A Rutter; David J Hodson
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

8.  Regulation of cAMP accumulation and activity by distinct phosphodiesterase subtypes in INS-1 cells and human pancreatic β-cells.

Authors:  Evan P S Pratt; Kyle E Harvey; Amy E Salyer; Gregory H Hockerman
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

Review 9.  Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy.

Authors:  Rui Guo; Tian Liu; Marzieh Dehghan Shasaltaneh; Xuan Wang; Saber Imani; QingLian Wen
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

10.  Strategies to safely target widely expressed soluble adenylyl cyclase for contraception.

Authors:  Jacob Ferreira; Lonny R Levin; Jochen Buck
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.